The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy.

[1]  D. Pavlović,et al.  Diabetic nephropathy: diagnosis, prevention and treatment , 2013 .

[2]  J. Myśliwska,et al.  Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. , 2013, Human immunology.

[3]  Yong Zhao,et al.  The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications , 2011, Journal of Molecular Medicine.

[4]  J. Navarro-González,et al.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy , 2011, Nature Reviews Nephrology.

[5]  C. Apovian,et al.  Elevated Proinflammatory Cytokine Production by a Skewed T Cell Compartment Requires Monocytes and Promotes Inflammation in Type 2 Diabetes , 2011, The Journal of Immunology.

[6]  Lin Qiu,et al.  Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice , 2011, Immunology and cell biology.

[7]  J. Ilonen,et al.  IL-17 Immunity in Human Type 1 Diabetes , 2010, The Journal of Immunology.

[8]  Yuh-Feng Lin,et al.  Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[9]  M. Levings,et al.  Translational Mini‐Review Series on Th17 Cells: Function and regulation of human T helper 17 cells in health and disease , 2010, Clinical and experimental immunology.

[10]  A. Chervonsky,et al.  Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. , 2010, The Journal of clinical investigation.

[11]  A. Saltiel,et al.  MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity , 2009, The Journal of experimental medicine.

[12]  D. Hafler,et al.  Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 Cells1 , 2009, The Journal of Immunology.

[13]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[14]  D. Bending,et al.  Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. , 2009, The Journal of clinical investigation.

[15]  J. Navarro-González,et al.  Pathogenic perspectives for the role of inflammation in diabetic nephropathy. , 2009, Clinical science.

[16]  S. Shankland,et al.  Proteinuria in diabetic kidney disease: a mechanistic viewpoint. , 2008, Kidney international.

[17]  E. Assier,et al.  Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. , 2008, Joint, bone, spine : revue du rhumatisme.

[18]  S. Zheng,et al.  Cutting Edge: Foxp3+CD4+CD25+ Regulatory T Cells Induced by IL-2 and TGF-β Are Resistant to Th17 Conversion by IL-61 , 2008, The Journal of Immunology.

[19]  Yong Chen,et al.  The Th17/Treg imbalance in patients with acute coronary syndrome. , 2008, Clinical immunology.

[20]  C. Baecher-Allan,et al.  Human regulatory T cells and autoimmunity , 2008, European journal of immunology.

[21]  J. Navarro-González,et al.  The role of inflammatory cytokines in diabetic nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.

[22]  S. John,et al.  CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages , 2007, Proceedings of the National Academy of Sciences.

[23]  M. Battaglia,et al.  Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans , 2007, Nature Reviews Immunology.

[24]  J. Chan,et al.  Aberrant activation profile of cytokines and mitogen‐activated protein kinases in type 2 diabetic patients with nephropathy , 2007, Clinical and experimental immunology.

[25]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[26]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[27]  J. Bluestone,et al.  How do CD4+CD25+ regulatory T cells control autoimmunity? , 2005, Current opinion in immunology.

[28]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[29]  D. Rachoń,et al.  High levels of circulating interleukin-10 in diabetic nephropathy patients. , 2005, European cytokine network.

[30]  G. Wolf.  New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology , 2004, European journal of clinical investigation.

[31]  C. Leclerc,et al.  Neonatal adaptive immunity comes of age , 2004, Nature Reviews Immunology.

[32]  M. Lopes-Virella,et al.  The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. , 2003, Frontiers in bioscience : a journal and virtual library.

[33]  E. Ritz,et al.  Diabetic nephropathy in type 2 diabetes prevention and patient management. , 2003, Journal of the American Society of Nephrology : JASN.

[34]  Masafumi Koga,et al.  Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. , 2003, Metabolism: clinical and experimental.

[35]  M. Mauer,et al.  Diabetes and nephropathy , 2003, Current opinion in nephrology and hypertension.

[36]  Giuseppe Remuzzi,et al.  Nephropathy in Patients with Type 2 Diabetes , 2002 .

[37]  M. Cooper,et al.  Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy , 2001, Diabetologia.

[38]  F. Locatelli,et al.  End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  S. Cohen,et al.  The frequency of Th2 type cells increases with time on peritoneal dialysis in patients with diabetic nephropathy. , 1999, European cytokine network.

[40]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[41]  Z. Bloomgarden.  American Diabetes Association Annual Meeting, 1997: Improvement of the quality of diabetes care , 1998, Diabetes Care.

[42]  Z. Bloomgarden.  American Diabetes Association Annual Meeting, 1997, and the Teczem Consultant Meeting: Diabetic nephropathy , 1998, Diabetes Care.

[43]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[44]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[45]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[46]  M. Arababadi,et al.  Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? , 2010, Diabetes research and clinical practice.

[47]  Chun-hong Zhang,et al.  [Role of CD4+CD25+Foxp3+ regulatory T cells in type 2 diabetic nephropathy]. , 2009, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.